One of the website for rare disease community – Rare Disease Report has shared exciting news about CentoMD® mutation database milestone – one billion collected alleles from over 200,000 patient samples.
We announce that results from the scientific research focused on biomarkers and genetic data for rare hereditary diseases will be the core of four poster presentations at the 14th Annual WORLDSymposium™. Read more on our website!
CentoMD® is the world’s largest global mutation database for rare genetic disorders, covering more than 3,300 associated phenotypes for patients in 115 countries. Read more how it provides information about the genotype-phenotype correlation based on tested clinical cases!
CENTOGENE´s New Years Reception was held on 24th January 2018th at CentoNew! CENTOGENE is proud and honored with the organization of the first New Year’s reception in our new headquarters, especially supported by the Management Board of CENTOGENE.
CENTOGENE, the worldwide leader in diagnosing, profiling, tracking and elucidating rare diseases for patients, clinicians and pharmaceutical partners, today announced that it will make a formal presentation at the 36th Annual J.P. Morgan Healthcare Conference.
Richard Stoffelen is our Chief Financial Officer and was recently acknowledge for his outstanding work by the FINANCE MONTHLY magazine.
CENTOGENE supports the global art project Ship of Tolerance, driven by the artists Ilya & Emilia Kabakov, where people from different continents, cultures and identities create a patchwork canvas to make a unique sail.
CENTOGENE and QIAGEN announce to collaborate in bioinformatics, aiding the analysis of hereditary disorders by integrating genomic and clinical databases. Read more!
An agreement of a new cooperation was signed between CENTOGENE, Germany and University Hospital “St. Ivan Rilski” Sofia, Bulgaria. Read more in our latest news!
CENTOGENE is proud to announce our Euro 25 million financing round. Read more in our latest news!
We have been working together for years with partners in developing biomarkers. This successful development has been financially supported by the Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH (MBMV).
We organized an interactive event on the occasion of Rare Disease Day 2017 at the Zoo Rostock. Read more!
Our new headquarter in Rostock, CentoNew, is growing rapidly – we started the countdown to our move-in November 2017. Read more!
CENTOGENE and Genetic Associates announce their strategic collaboration for the Australian/New Zealand market. Read more!
Dr. Arndt Rolfs, CEO CENTOGENE, presented at JP Morgan Healthcare Conference 2017 about CENTOGENE’s self-amplifying business model – diagnostics, proprietary tools (including the largest, fully curated mutation database for rare diseases – CentoMD®) and pharmaceutical partnerships.
